PLA2R1 Mediates Tumor Suppression by Activating JAK2VINDRIEUX, David; AUGERT, Arnaud; DE LAUNOIT, Yvan et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 20, pp 6334-6345, issn 0008-5472, 12 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

Phosphorylation of small peptides by spleen TPK-IIA, a tyrosine protein kinase stimulated by polylysine and by high ionic strengthBRUNATI, A. M; MARCHIORI, F; RUZZA, P et al.FEBS letters. 1989, Vol 254, Num 1-2, pp 145-149, issn 0014-5793, 5 p.Article

Receptor tyrosine kinase signaling and trafficking: Paradigms revisitedBARBIERI, M. A; RAMKUMAR, T. P; FERNADEZ-POL, S et al.Current Topics in Microbiology and Immunology. 2004, Vol 286, pp 1-19, issn 0070-217X, 19 p.Article

Light-regulated sampling of protein tyrosine kinase activityQUNZHAO WANG; ZHAOHUA DAI; CAHILL, Sean M et al.Journal of the American Chemical Society. 2006, Vol 128, Num 43, pp 14016-14017, issn 0002-7863, 2 p.Article

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsPARDANANI, A; VANNUCCHI, A. M; PASSAMONTI, F et al.Leukemia. 2011, Vol 25, Num 2, pp 218-225, issn 0887-6924, 8 p.Article

Targeting myeloproliferative neoplasms with JAK inhibitorsPARDANANI, Animesh; TEFFERI, Ayalew.Current opinion in hematology. 2011, Vol 18, Num 2, pp 105-110, issn 1065-6251, 6 p.Article

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disordersDAWSON, Mark A; CURRY, Jayne E; THOMPSON, Neil T et al.British journal of haematology. 2010, Vol 150, Num 1, pp 46-57, issn 0007-1048, 12 p.Article

Identification of JAK2^V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia veraGANLY, Peter; HANRAHAN, Vickie; BAKER, Bart et al.American journal of hematology. 2007, Vol 82, Num 1, pp 80-82, issn 0361-8609, 3 p.Article

Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: Dual inhibitors of EGFR and Src protein tyrosine kinasesJINSHENG LIN; WEI SHEN; JINGWEI XUE et al.European journal of medicinal chemistry. 2012, Vol 55, pp 39-48, issn 0223-5234, 10 p.Article

Src Kinase Mediates Productive Endocytic Sorting of Reovirus during Cell EntryMAINOU, Bernardo A; DERMODY, Terence S.Journal of virology. 2011, Vol 85, Num 7, pp 3203-3213, issn 0022-538X, 11 p.Article

The focal adhesion kinaseSCHALLER, M. D.Journal of endocrinology. 1996, Vol 150, Num 1, pp 1-8, issn 0022-0795, 7 p.Article

Tyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiationFILVAROFF, E; STERN, D. F; DOTTO, G. P et al.Molecular and cellular biology (Print). 1990, Vol 10, Num 3, pp 1164-1173, issn 0270-7306, 10 p.Article

T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substratesHSI, E. D; SIEGEL, J. N; MINAMI, Y et al.The Journal of biological chemistry (Print). 1989, Vol 264, Num 18, pp 10836-10842, issn 0021-9258, 7 p.Article

Src family tyrosine kinase Lyn mediates VWF/GPIb-IX-induced platelet activation via the cGMP signaling pathwayHONG YIN; JUNLING LIU; ZHENYU LI et al.Blood. 2008, Vol 112, Num 4, pp 1139-1146, issn 0006-4971, 8 p.Article

Proton demand inversion in a mutant protein tyrosine kinase reactionWILLIAMS, Daniel M; COLE, Philip A.Journal of the American Chemical Society. 2002, Vol 124, Num 21, pp 5956-5957, issn 0002-7863Article

Intrinsic Resistance to JAK2 Inhibition in MyelofibrosisKALOTA, Anna; JESCHKE, Grace R; CARROLL, Martin et al.Clinical cancer research (Print). 2013, Vol 19, Num 7, pp 1729-1739, issn 1078-0432, 11 p.Article

Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patientRAO, Nisha; BUTCHER, Carolyn M; LEWIS, Ian D et al.British journal of haematology. 2012, Vol 156, Num 2, pp 268-270, issn 0007-1048, 3 p.Article

The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issuesVAN ETTEN, Richard A; KOSCHMIEDER, Steffen; GALE, Robert Peter et al.Haematologica (Roma). 2011, Vol 96, Num 4, pp 590-601, issn 0390-6078, 12 p.Article

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosisGUGLIELMELLI, P; BIAMONTE, F; SPOLVERINI, A et al.Leukemia. 2010, Vol 24, Num 8, pp 1533-1537, issn 0887-6924, 5 p.Article

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasmsTYNER, Jeffrey W; BUMM, Thomas G; DEININGER, Jutta et al.Blood. 2010, Vol 115, Num 25, pp 5232-5240, issn 0006-4971, 9 p.Article

Clonal analysis of TET2 and JAK2 mutations suggests that TE7-2 can be a late event in the progression of myeloproliferative neoplasmsSCHAUB, Franz X; LOOSER, Renate; SAI LI et al.Blood. 2010, Vol 115, Num 10, pp 2003-2007, issn 0006-4971, 5 p.Article

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutationJAMAL, R; BELISLE, C; LESSARD, M.-C et al.Leukemia. 2008, Vol 22, Num 7, pp 1472-1474, issn 0887-6924, 3 p.Article

JAK2 Mutations are present in all cases of polycythemia veraWANG, Y. L; VANDRIS, K; JONES, A et al.Leukemia. 2008, Vol 22, Num 6, pp 1289-1289, issn 0887-6924, 1 p.Article